2359.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 05:44):

Stats
Šios dienos apimtis	4.69M
Vidutinė apimtis	10.39M
Rinkos kapitalizacija	136.46B
EPS	HKD0.940 ( 2023-10-31 )
Last Dividend	HKD0.989 ( 2023-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	10.56
ATR14	HKD0.107 (0.29%)

Tūris Koreliacija

Ilgas: 0.23 (neutral)

Trumpas: 0.34 (neutral)

Signal:(64.066) Neutral

WuXi AppTec Co., Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

WuXi AppTec Co., Ltd. Koreliacija - Valiuta/Žaliavos

0.38
( neutral )

0.47
( neutral )

0.00
( neutral )

0.63
( weak )

0.08
( neutral )

-0.84
( strong negative )

WuXi AppTec Co., Ltd. Finansinės ataskaitos

Annual	2023
Pajamos:	HKD40.34B
Bruto pelnas:	HKD16.61B (41.18 %)
EPS:	HKD3.27

FY	2023
Pajamos:	HKD40.34B
Bruto pelnas:	HKD16.61B (41.18 %)
EPS:	HKD3.27

FY	2022
Pajamos:	HKD39.35B
Bruto pelnas:	HKD14.68B (37.30 %)
EPS:	HKD3.15

FY	2021
Pajamos:	HKD22.90B
Bruto pelnas:	HKD8.31B (36.28 %)
EPS:	HKD1.820

Financial Reports:

No articles found.

WuXi AppTec Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.989 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

WuXi AppTec Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.38 - Increase likely (47.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.281	2019-06-17
Last Dividend	HKD0.989	2023-06-05
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	HKD2.45	--
Avg. Dividend % Per Year	0.00%	--
Score	3.55	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.38
Div. Directional Score	10.00	--

Next Divdend (Est)
(2025-03-31)

HKD1.307 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.55

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
87001.HK	Ex Dividend Junior	2023-08-10	Semi-Annually	0.00%
2107.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
1114.HK	Ex Dividend Junior	2023-08-11	Annually	0.00%
0189.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
3808.HK	Ex Dividend Junior	2023-07-04	Annually	0.00%
1696.HK	Ex Dividend Junior	2023-08-24	Annually	0.00%
0730.HK	Ex Dividend Junior	2023-05-24	Annually	0.00%
2283.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
1270.HK	Ex Dividend Knight	2023-05-16	Annually	0.00%
0323.HK	No Dividend Player	2023-06-21	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.238	1.500	5.24	7.86	[0 - 0.5]
returnOnAssetsTTM	0.130	1.200	5.65	6.78	[0 - 0.3]
returnOnEquityTTM	0.187	1.500	9.04	10.00	[0.1 - 1]
payoutRatioTTM	0.287	-1.000	7.13	-7.13	[0 - 1]
currentRatioTTM	2.06	0.800	4.69	3.75	[1 - 3]
quickRatioTTM	1.610	0.800	5.24	4.19	[0.8 - 2.5]
cashRatioTTM	0.933	1.500	5.93	8.89	[0.2 - 2]
debtRatioTTM	0.0780	-1.500	8.70	-10.00	[0 - 0.6]
interestCoverageTTM	61.33	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	4.20	2.00	8.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.35	2.00	8.83	10.00	[0 - 20]
debtEquityRatioTTM	0.104	-1.500	9.58	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.412	1.000	6.47	6.47	[0.2 - 0.8]
operatingProfitMarginTTM	0.294	1.000	6.11	6.11	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.18	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.548	0.800	9.68	7.75	[0.5 - 2]
Total Score				12.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.12	1.000	9.08	0	[1 - 100]
returnOnEquityTTM	0.187	2.50	9.38	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.35	2.00	9.22	10.00	[0 - 30]
dividendYielPercentageTTM	3.04	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.20	2.00	8.60	10.00	[0 - 30]
payoutRatioTTM	0.287	1.500	7.13	-7.13	[0 - 1]
pegRatioTTM	0.503	1.500	9.98	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.311	1.000	4.74	0	[0.1 - 0.5]
Total Score				7.38

WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.